logo
Share SHARE
FONT-SIZE Plus   Neg

Ipsen Renegotiates 2010 Strategic Partnership Agreement With Inspiration

Ipsen (IPSEF.PK) announced the renegotiation of its 2010 strategic partnership agreement with Inspiration Biopharmaceuticals, Inc. for the development and commercialization of Inspiration's recombinant product portfolio - OBI-1, a recombinant porcine factor VIII (rpFVIII) being developed for treating patients with acquired hemophilia A and congenital hemophilia A with inhibitors, and IB1001, a recombinant factor IX (rFIX) for the treatment and prevention of bleeding in patients with hemophilia B.

As per the new agreement and in its territories, Ipsen recovers commercial rights to OBI-1. Also, Ipsen is granted commercial rights for IB1001. As a result, Ipsen will record sales of OBI-1 and IB1001 in its drug sales line. Ipsen will further pay Inspiration a mid-teen royalty on OBI-1 sales and a higher double digit royalty on IB1001's sales.

In addition, under the new terms, Ipsen has agreed to invest up to $20 million in Inspiration.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cable-cutters have now one more reason to do so as live television streaming will be available on YouTube TV in 14 more markets in the U.S. Facebook Chief Operating Officer Sheryl Sandberg has donated nearly $100 million in Facebook shares to charity. This is her second charitable donation within a year. A document was filed on Thursday with the Security and Exchange Commission, which shows that Sandberg transferred shares to a special fund she uses for charitable donations. Ford Motor Co.'s new CEO Jim Hackett has taken a more cautious approach to the automaker's plans for rolling out autonomous vehicles. Ford is currently undertaking a 100-day review of its operations and Hackett indicated at delays to the company's plans to launch a fully-autonomous vehicle by 2021.
comments powered by Disqus
Follow RTT